Interleukin-3 (IL-3) expression by tumor-infiltrating lymphocytes (TILs) and its effects on vessel assembly were evaluated. TILs from 'in situ' human breast cancers expressed CD4/CD25 antigens and IL-3. An injection of Matrigel containing SMC and IL-3 or basic-fibroblast growth factor (bFGF) into SCID mice confirmed the neoangiogenetic effect of both factors. However, in response to IL-3, but not to bFGF, only few SMC became incorporated into the nascent vessels. To evaluate the possibility that signals emanated by the nascent vasculature in the presence of IL-3 may negatively regulate SMC recruitment, conditioned media (CM) from IL-3-treated endothelial cells (EC) or SMC were tested for their biological effects on SMC and EC. CM from IL-3-treated SMC stimulated the migration of EC. In contrast, the migration of SMC was not affected by CM from IL-3-stimulated EC; however, it was greatly enhanced by blocking transforming growth factor b (TGFb) activity. TGFb immunoenzymatic assay demonstrated the following: (i) the absence of TGFb activity in CM from IL-3-stimulated EC; (ii) a barely detectable TGFb activity in CM from IL-3-stimulated SMC; and (iii) the presence of TGFb activity in the supernatants of SMC stimulated with CM from IL-3-, but not from bFGF-stimulated EC. Increased TGFb mRNA expression was only detected in SMC stimulated with CM from IL-3-treated EC. Finally, the inhibitory signals induced by IL-3 in vivo were abrogated by the addition of the neutralizing TGFb antibody. Thus, the positive immunostaining for IL-3 by TILs in 'in situ' breast cancers sustains the possibility that early in tumor development, IL-3 can contribute to the chronic immaturity of these vessels.
Introduction
The de novo organization of endothelial cells (EC) into vessels in the absence of any pre-existing vascular system is referred to as vasculogenesis, and only occurs in the early embryonic life (Beck and D'Amore, 1997) . The continued expansion of the vascular tree as a result of EC sprouting from existing vessels, denoted as angiogenesis, occurs in the vascular region of embryo and is repeated many times in adulthood most commonly during would healing and tumor (Hanahan and Folkman, 1996; Risau, 1997) . Further maturation of blood vessels, which mature or regress, depends on intra-and extraluminal factors. Initially, it only depends on the oxygen level, and later, forces generated by circulation affect EC by inducing cell-cell and cell-matrix junctions and by upregulating factors, such as platelet-derived growth factor (PDGF)-BB and transforming growth factor (TGF)b (Darland and D'Amore, 1999) . These soluble mediators seem to be the main factors involved in vessel maturation, a biological process mainly consisting in the recruitment of pericytes (Hirschi et al., 1998) .
As developing organisms, the growth of tumors is believed to require the induction of new tumor blood vessels, following the same steps of physiological neoangiogenesis. The angiogenic switch is also a crucial event in tumor progression, which is attributed in large part to the production of angiogenic factors by tumor cells and also by tumor-associated host cells (Balkwill and Mantovani, 2001 ) including T-lymphocytes (Balch et al., 1990) . Infiltrates of T-lymphocytes have been considered protective against tumor; however, only a small proportion of tumor-infiltrating lymphocytes have been shown to recognize tumor cells specifically (Itoh et al., 1988; Finke et al., 1990; Peoples et al., 1993) . Thus far, it has been difficult to correlate the degree of lymphocyte infiltration and clinical outcome (Wintzer et al., 1991) . Clearly, in most cancers, despite lymphocytes infiltration, tumor progresses, suggesting that, besides a protective role, lymphocytes may affect tumor progression. Actually, by releasing soluble mediators, they may modulate tumor growth as suggested by the in vivo angiogenic properties of some of these mediators (Peoples et al., 1995) . The description of a unique subset of T-lymphocytes CD4 and CD25-positive that not only plays an important function in maintaining immune homeostasis (Shevach, 2001 ) but also abundantly infiltrates invasive tumors as non-small-lung carcinoma, ovarian cancers (Woo et al., 2001) , pancreatic and breast carcinomas (Liyanage et al., 2002) , sheds some light on a novel function of tumor-infiltrating lymphocytes (TILs). Ex vivo studies of these cells reveal a poorly proliferative cell population mainly secreting TGFb and IL-10 (Dieckmann et al., 2001) .
Among the cytokines produced by the CD4 subset of cells is included interleukin-3 (IL-3) (Wimperis et al., 1989) . IL-3 has been originally described as a specific hematopoietic cytokine involved in the proliferation of progenitor cells, terminal differentiation of committed myeloid lineages and functional activation of differentiated cells (Clark and Kamen, 1987) . Subsequently, we (Brizzi et al., 1993; Dentelli et al., 1999) and others (Korpelainen et al., 1993) demonstrated that IL-3 was also able to promote proliferation, migration and functional activation of EC as well as in vivo neoangiogenesis (Dentelli et al., 1999) . Moreover, more recently we reported that IL-3 can be expressed by plaqueinfiltrating lymphocytes and that upon release can activate the proliferation and migration of SMC (Brizzi et al., 2001) . These effects, exerted on both EC and SMC, raised the possibility that IL-3 may also affect the functional activity of vascular cells where developmental events are recapitulated as in tumor angiogenesis. It is well established that, in contrast to normal vasculature, tumor vessels are structurally and functionally abnormal, showing an immature phenotype characterized by a relative absence of mural cells. This phenotype seems to be the result of an unbalance between positive and negative angiogenic regulators, such as VEGF and angiopoietin (Benjamin et al., 1999; Holash et al., 1999) . Although several data are available on the pivotal role played by EC in governing vessel maturation (Hirschi et al., 1998; Darland and D'Amore, 1999) , so far no data have been reported on the role exerted by cytokines and growth factors present in the microenvironment of developing vessels.
The aims of the present study were to investigate the ability of TILs to produce IL-3 and the role played by IL-3 in vessel assembly.
Results

IL-3 expression by TILs
Despite significant infiltration into tumors, the role of activated T-lymphocytes is not completely defined (Balch et al., 1990) . However, by releasing soluble mediators they can contribute to modulate tumor growth as indicated by the ability of TILs to produce bFGF-and heparin-binding epidermal growth factorlike growth factor (Peoples et al., 1995) . The CD4 subset of activated T-lymphocytes are known to be the main IL-3-producing cells (Wimperis et al., 1989) . To evaluate whether TILs also expressed IL-3, immunofluorescence analysis was performed on 20 different 'in situ' breast cancer samples showing non-high-grade or high-grade lesions (Silverstein et al., 1995) , as reported in Table 1 . Sections from paraffin-included fresh tumors were double immunostained with a monoclonal anti-IL-3 antibody (red) and a polyclonal anti-CD25 antiserum (green) that recognized activated T-cells. The results shown in Figure 1 representative of non-high-grade ( Figure 1b ) and high-grade lesion (Figure 1e ) demonstrated that CD25-positive cells expressed in the high-grade lesions. Owing to the absence of inflammatory infiltrates in non-high-grade lesions (hematoxylin-eosin-staining in Figure 1a ), no CD25-positive cells could be detected (Figure 1b ). It has been recently shown that a subset of T-lymphocytes, expressing CD4 and CD25 antigens (Shevach, 2001 ) and denoted as regulatory T-cells, infiltrate advanced tumors (Woo et al., 2001; Liyanage et al., 2002) . We therefore evaluated whether this subset of T-cells were also present in early tumor lesions. The results of the double immunostaining using the anti-CD4 and anti-CD25 antibodies (representatively in Figure 1h ) demonstrate that the CD4/CD25-positive cells (merged) also infiltrate the 'in situ' breast cancer specimens. Moreover, the double immunostaining with the polyclonal anti-CD4 (green) and the monoclonal anti-IL-3 antibody (red) demonstrated that, as previously shown by Wimperis et al. (1989) in inflammatory tissues, the CD4-positive cells infiltrating 'in situ' tumor lesions are also positive for IL-3 (merged in Figure 1f ). As negative control, nonimmune mouse (Figure 1i ) or rabbit (data not shown) IgG was used in place of primary antibodies. Immunostaining for CD5, another surface marker of regulatory T cells (Woo et al., 2001; Liyanage et al., 2002) , was performed in some specimens and, as reported in Table 1 , a positive immunoreactivity was detected. Therefore, these results demonstrate that the subset of CD4-and CD25-expressing T-cells also 
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Neovessels show an impaired SMC recruitment in an in vivo model of angiogenesis
We previously reported that IL-3 not only enhances vessel formation (Dentelli et al., 1999) but also affects the ability of SMC to undergo proliferation and migration (Brizzi et al., 2001) . The ability of IL-3 to regulate SMC recruitment by newly formed vessels has been evaluated in an in vivo model. To this end, Matrigel containing heparin, IL-3 and fluorescent-labeled human SMC was injected s.c. into SCID mice. bFGF was used as control. After 6 days, SCID mice were killed and the Matrigel plugs were excised and processed for immunofluorescence analysis using an anti-CD105 antibody to detect EC. As previously reported (Dentelli et al., 1999) , IL-3 was able to induce neoangiogenesis ( Figure 2a) ; however, only few red-labeled SMC surrounded neovessels ( Figure 2b ). By contrast, when neoangiogenesis ( Figure 2c ) and SMC incorporation ( Figure 2d ) were evaluated in bFGF-treated SCID mice, the neoformed vessels were completely surrounded by the red-labeled SMC (Figure 2d ). Similar results were obtained when SCID mice were killed after 10 days. No vessel formation could be detected in the absence of IL-3 or bFGF (data not shown), and SMC were scattered in the Matrigel area when analysed in immunofluorescence (data not shown). The quantification of neovascularization was performed on hematoxylin-eosin-stained histologic sections and expressed as the percentage of the vessel area to the total Matrigel area, as previously described (data not shown) (Dentelli et al., 1999) .
Motogenic response to CM from IL-3-stimulated cells
The in vivo results opened some questions on the possible role played by IL-3 when SMC and EC are both present. However, since both EC and SMC migrate and proliferate in response to IL-3 in vitro coculture cannot be a useful model to discriminate between direct and indirect responses of the cells to the IL-3 treatment.
To overcome this problem, EC and SMC were separately stimulated with IL-3 and the CM recovered after stimulation were tested on the counterpart. We found that CM from IL-3-stimulated SMC exerted motogenic activity on EC. A dose-response curve (CM from 0.5 to 50%) (data not shown) demonstrated that the maximal motogenic activity was achieved with 10% final concentration (Figure 3a) . By contrast, CM from IL-3-treated EC at 10% final concentration (3c) failed to stimulate SMC migration. Similar results were obtained with different concentrations (from 0.5 to 50%) of CM (data not shown). To exclude the possibility that residual IL-3 contained in the CM might account for EC migration, a blocking anti-IL-3 antiserum was used. As shown in Figure 3a , the blocking antiserum did not affect either EC or SMC migration. As positive control for both EC and SMC migration assay, VEGF was used. As previously reported (Wang and Keiser, 1998; Ishida et al., 2001) , SMC express VEGF receptor 2 (VEGFR2/KDR) (Figure 3b ). Representative specimens obtained from nonhigh nuclear grade (ac) or from high nuclear grade (d-i) 'in situ' breast carcinomas were subjected to hematoxylin/eosin-staining (a, d and g) or to a double immunofluorescence using an anti-CD25 polyclonal antiserum (green) and a monoclonal anti-IL-3 (red) antibody (b and e), or an anti-CD4 polyclonal antiserum (green) and a monoclonal anti-IL-3 (red) antibody (c and f). FITC-conjugated anti-rabbit IgG and RITC-conjugated anti-mouse were used as secondary antibody to recognize CD25 or CD4 and IL-3, respectively. Note a doublepositive immunostaining for CD25 and IL-3 and for CD4 and IL-3 (yellow). A double immunofluorescence using an anti-CD4 polyclonal antiserum (green) and a monoclonal anti-CD25 (red) is also shown (h). FITC-conjugated anti-rabbit IgG and RITCconjugated anti-mouse were used as secondary antibody to recognize CD4 and CD25, respectively. Colocalization of both antigens is merged. As negative control, nonimmune mouse IgG was used in place of primary monoclonal antibodies (i)
IL-3 and vessel stabilization P Dentelli et al IL-3 stimulates MMP2 enzymatic activity and VEGF synthesis both in EC and SMC MMP-2, which is secreted by EC and SMC (Lewalle et al., 1995; Kenagy et al., 1997) , can participate, upon activation from the latent zymogen form, in the degradation of interstitial collagen thus regulating cell migration. To evaluate whether differences in MMP2 activity might account for the effects on EC and SMC migration, CM from IL-3-stimulated EC and SMC were assayed for gelatin-zymography. Figure 4a and b shows the dose-response curves and the kinetic of MMP2 enzymatic activity in EC and SMC, respectively. The representative zymogram depicted in Figure 4c (showing a band of 72 kDa, corresponding to MMP2 proenzyme, and two lower molecular weight species of 62 and 59 kDa corresponding to MMP2 enzymatic activated proteins) demonstrated an increased gelatinolytic activity after IL-3 stimulation in both cell types. The specificity was demonstrated by the addition of a blocking anti-IL-3 antiserum that completely abrogated this effect ( Figure 4c ). It is known that VEGF may also act as a chemotactic modulator on both EC and SMC (Wang and Keiser, 1998; Ferrara, 1999; Grosskreutz et al., 1999; Ishida et al., 2001) . To evaluate the possibility that VEGF might account for the different biological responses, the ability of EC and SMC to release VEGF after 18 h of IL-3 treatment was analysed by Western blot. As shown in Figure 4d , no differences in VEGF production were observed and the blocking anti-IL-3 antiserum abrogated this effect.
Thus, these findings demonstrate that the different motogenic effects exerted by CM from stimulated EC and SMC do not depend on MMP2 activity and VEGF production.
EC migration in response to CM from stimulated SMC depends on MMP2 activity and VEGF
The observations that in response to IL-3 either EC or SMC can release VEGF and activate MMP2 enzymatic activity led us to evaluate their involvement in regulating cell migration. To this end, the ability of EC to migrate in response to CM from IL-3-stimulated SMC was evaluated in the presence of blocking anti-MMP2 and anti-VEGF antibodies. As shown in Figure 5 , both antibodies were able to reduce EC migration drastically, while a complete inhibitory effect was achieved by the combined use of both antibodies. The specificity of the anti-VEGF antibody was demonstrated by the inhibitory effect observed in response to VEGF but not to IL-3.
SMC-derived TGFb activity is induced directly and indirectly by IL-3 but not by bFGF
TGFb can be released by vascular cells in some pathological conditions (McCaffrey, 2000) and its inhibitory effect on EC and SMC migration and proliferation has been extensively demonstrated (McCaffrey, 2000) . Therefore, we first evaluated whether the effect exerted by CM from IL-3-treated , VEGF (10 ng/ml), IL-3 (20 ng/ml), IL-3 pre-incubated with the anti-IL-3 antiserum (40 mg/ml), the anti-IL-3 antiserum (40 mg/ml), CM from untreated or 18 h IL-3-stimulated SMC at 10% final concentration alone or preincubated with the anti-IL-3 antiserum (40 mg/ml). ANOVA with Newman-Keuls multicomparison test was performed: control vs experimental groups: *, Po0.05; IL-3 vs IL-3 plus anti-IL-3 antiserum: y, Po0.05. (b) EC and SMC were lysed in cold DIM buffer (Brizzi et al., 1999b) . Equal amounts of proteins (500 mg) were immunoprecipitated (IP) with an anti-VEGFR2/KDR antiserum and subjected to 8% SDS-PAGE. Proteins were electrophoretically transferred onto a nitrocellulose filter and immunoblotted (IB) with an anti-VEGFR2/KDR antiserum. (c) SMC migration. SMC migration induced by: vehicle alone (control), VEGF (10 ng/ml), IL-3 (20 ng/ml), IL-3 pre-incubated with the anti-IL-3 antiserum (40 mg/ml), the anti-IL-3 antiserum (40 mg/ml), CM from untreated EC, CM from IL-3-stimulated EC at 10% final concentration alone or preincubated with the anti-IL-3 antiserum (40 mg/ml Figure 6a , in the presence of the neutralizing antiTGFb antibody, SMC acquired the ability to migrate in response to both CM, suggesting that, in response to IL-3, EC (either macrovascular or microvascular cells), SMC or both may release TGFb activity. To assess this possibility, an immunoenzymatic assay for TGFb was performed. As depicted in Figure 6b , we failed to detect the release of TGFb activity by IL-3-stimulated EC and Representative zymogram of serum-free CM from EC and SMC treated or untreated (-) with IL-3 or IL-3 plus the anti-IL-3 antiserum as indicated. CM were collected after 18 h, normalized to cell number and aliquots corresponding to equal amounts of cells were subjected to gelatin zymography. As positive control, human serum was used. The position of MMP-2 pro-enzyme and of two forms of the activated enzyme are indicated. (d) VEGF synthesis upon IL-3 treatment. Supernatants from EC or SMC unstimulated (-), or stimulated with IL-3 (20 ng/ ml) or IL-3 plus the anti-IL-3 antiserum were normalized to the cell number and subjected to 15% SDS-PAGE. Proteins were electrophoretically transferred onto nitrocellulose filters and immunoblotted with an anti-VEGF antiserum. As control, H 2 O 2 -treated EC (Chua et al., 1998) and rhVEGF (2 ng/ml) were used. Similar results were obtained in three different experiments vehicle alone (control), VEGF (10 ng/ml) alone or in combination with an anti-VEGF (20 mg/ml) neutralizing antibody, IL-3 (20 ng/ ml) alone or in combination with an anti-VEGF (20 mg/ml) neutralizing antibody, CM from IL-3-stimulated SMC alone or in combination with an anti-VEGF (20 mg/ml) or with an anti-MMP-2 (4 mg/ml) neutralizing antibodies or with both neutralizing antibodies. The anti-VEGF and the anti-MMP2 antibodies were also used alone. ANOVA with Newman-Keuls multicomparison test was performed: control vs experimental groups: *Po0.05; CM from IL-3-treated SMC vs CM from IL-3-treated SMC plus anti-VEGF, CM from IL-3-treated SMC plus anti-MMP-2, CM from IL-3-treated SMC plus anti-VEGF and anti-MMP-2, or VEGF vs VEGF plus anti-VEGF: y, Po0.05. The migration assay was performed as described in Materials and methods. The numbers are the mean7s.e.m. of cells counted per 10 fields ( Â 200) of five individual experiments IL-3 and vessel stabilization P Dentelli et al CDC-HMEC-1 cells (data not shown), and only a small amount of TGFb was found to be released by IL-3-stimulated SMC. The small amount of TGFb produced by SMC could not account for the inhibitory effect exerted on migration (as demonstrated by motogenic experiments not reported), thus we speculated that, in response to IL-3, a paracrine response of EC commits SMC to release TGFb. To validate the possibility that SMC, in the presence of CM from IL-3-stimulated EC, released TGFb activity, an immunoenzymatic assay was performed on supernatants recovered from SMC at different time intervals. As shown in Figure 6c , TGFb activity picked up at 18 h following stimulation with CM from treated but not from untreated EC. Similar results were obtained using the microvascular-derived CDC-HMEC-1 cell line (Figure 6c) . To investigate whether the indirect effect of IL-3 on TGFb release could also be shared with other regulators of vessel formation, the ability of SMC to release TGFb in response to CM from bFGF-treated EC was evaluated. As shown in Figure 6d , no TGFb activity could be recovered in such experimental conditions. Indeed, SMC migration (Figure 6e) , performed in the presence of CM from bFGF-treated EC, was stimulated. Similarly, pretreatment with a neutralizing anti-TGFb antibody could not affect SMC migration. Thus, as indicated by the study of Hirschi et al. (1998) , and sustained by our in vivo results (Figure 2d) , it is tempting to speculate that, although both IL-3 and bFGF stimulate vessel formation, they diverge on the signals regulating SMC recruitment.
CM from IL-3-treated, but not from untreated, EC induce TGFb mRNA expression
We thereafter investigated the mechanisms regulating TGFb release in response to CM from IL-3-treated EC. TGFb activity is known to be increased not only by proteases, which activate the latent TGFb in the extracellular matrix, but also by alternative mechanisms mainly involving transcription of the gene (Nunes et al., 1996; Derynck et al., 2001; Oft et al., 2002; Wakefield and Roberts, 2002) . To test these possibilities, the release of TGFb was first evaluated in the presence of a blocking anti-MMP2 antibody or in the presence of the well-known protein synthesis inhibitor CHX. The results shown in Figure 6d demonstrate that the blocking anti-MMP2 antibody did not affect the release of TGFb activity. By contrast, the addition of CHX to SMC cultured in the presence of CM from IL-3-treated EC completely abrogates the release of TGFb activity, suggesting that newly synthesized TGFb may account for the recovered activity. To further validate this possibility, the TGFb mRNA expression was evaluated in SMC cultured in the presence of CM from untreated or IL-3-treated EC. Northern blot analysis reported in Figure 6f demonstrated that unlike CM from untreated EC, CM from IL-3-treated EC was able to increase the TGFb mRNA expression and that in line with the results of the immunoenzymatic assay, this effect was completely abolished by pretreatment with CHX.
SMC recruitment by neoformed vessels can be rescued by neutralizing TGFb activity
To confirm the above in vitro data, a neutralizing antiTGFb antibody was added to the Matrigel plugs injected into SCID mice. As shown in Figure 7a -f, the impaired SMC recruitment by neovessels formed in response to IL-3 (Figure 7e ) was restored in the presence of the anti-TGFb antibody (Figure 7f ), but not of a nonimmune IgG used as control (data not shown). The anti-TGFb alone did not affect neoangiogenesis (data not shown). Moreover, consistent with the notion that vessel stabilization negatively regulates vessel growth, the analysis of vessel areas demonstrated that, in the presence of the anti-TGFb antibody, a decreased number of neovessels was detected (Figure 7g) . No effect in the number of neoformed vessels and in SMC recruitment was detected when the anti-TGFb antibody was included in the Matrigel plugs together with bFGF (data not shown).
Discussion
In the present study, we demonstrate the presence of CD4-and CD25-positive T-cells, expressing IL-3, in nonadvanced tumors. Our observation that TILs express an angiogenic factor, such as IL-3, that may were starved and incubated for 18 h at 371C in the absence or in the presence of IL-3 (20 ng/ml). CM were collected and processed by EIA assay according to the manufactured protocol as described in Materials and methods. Data represent the mean7s.e.m. of three different experiments, each performed in triplicate (control vs experimental groups *Po0.05). (c) Kinetic of TGFb activity release. SMC were cultured in the presence of CM from untreated (J) or IL-3-treated EC (') or in the presence of CM from unstimulated (m) or IL-3-stimulated CDC-HMEC-1 (}). The collected supernatants were evaluated at different time intervals for the release of TGFb activity. The results are the mean7s.e.m. of three individual experiments. (d) Effect of CM from IL-3-or bFGF-stimulated EC on the release of TGFb activity by SMC. SMC were treated with CM from unstimulated and bFGF-or IL-3-stimulated EC with or without the anti-IL-3 antiserum (40 mg/ ml), the neutralizing anti-MMP2 antibody (4 mg/ml) or CHX (20 mg/ml). After 18 h of incubation, CM were collected and processed by EIA assay according to the manufactured protocol as described in Materials and methods. Data represent the mean7-s.e.m. of three different experiments, each performed in triplicate (control vs experimental groups y, Po0.05; CM-IL-3-treated EC vs CM-IL-3-treated EC plus CHX *, Po0.05). (e) SMC migration in response to CM from bFGF-stimulated EC. SMC migration induced by: vehicle alone (control), VEGF (10 ng/ml), bFGF (10 ng/ml), CM from untreated EC, CM from IL-3-treated EC, CM from bFGF-treated EC alone or in combination with the neutralizing anti-TGFb antibody (20 mg/ml). ANOVA with Newman-Keuls multicomparison test was performed: control vs experimental groups: *, Po0.05. The numbers are the mean7 s.e.m. of cells counted per 10 fields ( Â 200) of five individual experiments, each performed in triplicate. (f) TGFb gene expression on SMC in response to CM from IL-3-treated EC. Serumdeprived SMC were incubated for 12 h with CM from untreated or IL-3-treated EC in the absence or in the presence of CHX (20 mg/ ml). The total cytoplasmic RNA was isolated by phenol-chloroform extraction. Northern blot analysis was performed according to standard methods, and filters were hybridized with specific TGFb or b-actin cDNA probes. As control, thrombin-stimulated mesangial cells were used IL-3 and vessel stabilization P Dentelli et al support tumor growth and progression is particularly disconcerting since TILs have generally been regarded as protective. The fact remains that only a small fraction of TILs has been shown to display antitumor activity. It has been recently described that a subset of Tlymphocytes bearing CD4 and CD25, also known as T regulatory cells, plays an important role in maintaining immune homeostasis and in protecting the host against autoimmune diseases (Shevach, 2001 ). The observation that T regulatory cells abundantly infiltrate invasive tumors (Woo et al., 2001; Liyanage et al., 2002) raises the possibility that their presence may mitigate the host immune response against cancer. Our finding that CD4-and CD25-positive cells are already present in the tumor microenvironment at the early stage of tumor growth, although does not provide a mechanistic explanation, raises the possibility that they may represent the physiological response to most self-antigens borne by cancer cells. Indeed, there are evidences to suggest that the inflammatory cells infiltrating tumors potentiate neoplastic progression via paracrine factors mainly acting on tumor vascularization (Peoples et al., 1995) . Tumors, in a more natural setting, do not always originate avascularly, particularly when they arise within vascularized tissue where tumor cells coopt existing blood vessels (Holash et al., 1999) . Thus, the production of IL-3 by TILs sustains the possibility that the released cytokine could amplify the angiogenic response promoted by other soluble mediators, and possibly contribute to regulate the interplay between this coopting of existing vessels and subsequent tumor-induced angiogenesis. Moreover, the recent finding that IL-3 can also be produced by tat-expressing neoplastic ECs (Deregibus et al., 2002) suggests that IL-3 production may be a common feature in tumors.
During vessel formation, cells of the vessel wall are added at the later stages of vessel assembly (Darland and D'Amore, 1999) . The analysis of the developmental sequence suggests that, when the level of VEGF decreases, EC, possibly via the release of soluble factors, are responsible for the acquisition of mural cell layer (Darland and D'Amore, 1999) . Indeed, consistent with the lack of pericytes in some vascular beds of mice null for PDGF B (Lindahl et al., 1997) , in vitro studies showed that recruitment of mural cells is governed by EC, via the release of PDGF BB (Hirschi et al., 1998) . These observations sustain the notion that, during vessel development, stabilization of the vascular tree depends on a balance between stimulators and inhibitors acting in the context of the vessel microenvironment.
We have recently reported that IL-3, besides the effects exerted on EC, also promotes the proliferation and migration of SMC and triggers VEGF expression (Brizzi et al., 2001) . However, despite the finding that IL-3 was able to elicit these effects on isolated SMC (Brizzi et al., 2001) , our present in vivo data demonstrate that the recruitment of SMC by the vessels formed in response to IL-3 is impaired, suggesting that the microenvironment of developing vasculature may counteract the response to IL-3 observed on isolated SMC. To dissect the mechanisms that led to the impaired 5 SMC and IL-3 (20 ng/ml) alone (a, c and e) or in combination with neutralizing anti-TGFb antibody (20 mg/ml) (b, d and f) were subjected to hematoxylin/eosin staining (a and b) or subjected to immunofluorescence with an anti-CD105 antibody (c and d). The red SMC surrounding the new vessels are shown in (e) and (f). Five different sections from each individual experimental group (six mice per group) were analysed. (g) Effect of anti-TGFb antibody on vessel area formation in response to IL-3 in vivo. Matrigel plugs, containing 64 U/ml heparin with vehicle alone (control) or IL-3 (20 ng/ml), alone or in combination with the anti-TGFb antibody (20 mg/ml), or bFGF (10 ng/ml), were also injected s.c. into SCID mice. After 6 days, Matrigel plugs were excised and processed for light microscopy. The quantification of neovascularization was performed on hematoxylin-eosin-stained sections, as described in Materials and methods, and the results were expressed as percentage7s.d. of the vessel area to the total Matrigel area. Five different sections from each individual experimental group (six mice per group) were analysed. ANOVA with Newman-Keuls multicomparison test was performed: control vs experimental groups: *Po0.05; IL-3 vs IL-3 plus anti-TGFb antibody: $, Po0.05 IL-3 and vessel stabilization P Dentelli et al vessel maturation observed in vivo, the response of EC and SMC to CM from IL-3-stimulated counterpart was analysed in an in vitro system. We found that, as for CM from noncontacting coculture of both mesenchymal cells and EC (Hirschi et al., 1999) , when CM from IL-3-stimulated EC or SMC was assayed on the counterpart, the growth of both cell types was inhibited (data not shown). This finding suggests that the release of VEGF by both EC and SMC in response to IL-3 is not sufficient to counteract the inhibitory signals emanated by vascular cells. However, the release of VEGF and of activated MMP2 by SMC, in response to IL-3 challenge, substantially contributed to the migratory effect exerted by the CM on EC. The collagenase IV degrading enzyme MMP2 is known to act by degrading the component of the basement membrane to which EC attach (Lewalle et al., 1995; Kenagy et al., 1997) . Thus, IL-3 by inducing MMP2 activity, might render EC competent to the chemoattractant effect of VEGF leading to EC migration. Conversely, although EC secreted MMP2 and VEGF upon IL-3 treatment, we failed to detect SMC migration in response to CM from stimulated EC, suggesting that the release of inhibitory factor(s) can counteract their effects. The inhibitory role played by TGFb on SMC migration is well documented (McCaffrey, 2000) . Indeed, TGFb exerts potent and diverse actions on each of the cell types involved in vascular diseases, and, in many biological systems, it exerts bifunctional effects that depend upon the context in which the particular cell type encounters TGFb signal. Biologically, this context-dependent effect would allow TGFb to orchestrate an entire process that might involve opposite effects at different times. Coculture studies have shown that contact between EC and mural cells leads to the activation of TGFb, but the growthsuppressive effect of coculture was not dependent on TGFb (Hirschi et al., 1998) . Herein we report that SMC, but not EC, can release a small amount of activated TGFb when treated with IL-3. It is known that TGFb exerts a strong inhibitory effect on the proliferation and migration of EC (McCaffrey, 2000) . However, because of the small amount of TGFb activity released by SMC in response to IL-3, no inhibition of EC migration was detected. On the contrary, the finding that the migration of SMC in response to CM from IL-3-stimulated EC was enhanced by blocking the TGFb activity identifies TGFb as the inhibitory effector of SMC migration.
Different mechanisms may account for the increase of TGFb activity, including metalloprotease-mediated activation and induction of tgfb gene expression (Derynck et al., 2001; Oft et al., 2002; Wakefield and Roberts, 2002) . IL-3-treated EC released MMP2 activity that could account for the activation of TGFb (Nunes et al., 1996) , secreted in a latent form by SMC. However, this possibility was ruled out by the observation that a blocking anti-MMP2 antibody did not reduce the amount of TGFb activity released by SMC in response to CM from IL-3-treated EC. By contrast, our finding that CM from IL-3-treated EC was able to increase the TGFb mRNA expression, and that CHX abrogates both the expression and the release of TGFb activity by SMC indicates that a 'de novo' synthesis of TGFb occurred in our experimental conditions. During developmental angiogenesis, acquisition of mural cells by the vascular tree seems to regulate vessel stabilization by inhibiting EC proliferation and migration as well as by acting on SMC differentiation, integrin profiles and extracellular matrix production and accumulation (Roberts and Sporn, 1996) . Similarly, we herein demonstrate that upon the neutralization of TGFb activity, SMC recruitment is restored and that acquisition of these cells by the vascular tree elicits stabilizating signals counteracting vascular growth. That this effect is specifically induced by IL-3 is sustained by the following observations: (i) in the in vivo model, neovessels formed in response to bFGF were surrounded by SMC; (ii) CM from bFGFstimulated EC did not suppress SMC migration; and (iii) no TGFb activity was found in CM from bFGFstimulated EC.
The role played by TGFb in tumors is controversial (Derynck et al., 2001; Oft et al., 2002; Wakefield and Roberts, 2002) : in contrast with the observation that mice overexpressing TGFb have a decreased incidence of tumors, it is becoming evident that TGFb can promote tumor progression (Derynck et al., 2001; Oft et al., 2002; Wakefield and Roberts, 2002) , possibly by inducing invasion and angiogenesis (Bandyopadhyay et al., 1999; Rowland-Goldsmith et al., 2001) . Tumor vessels seem to be trapped in a cycle where the high level of angiogenic growth factors parallels the relative absence of mural cells (Darland and D'Amore, 1999) . In agreement with the in vivo observations, our results both from macrovascular and microvascular endothelium provide evidences that IL-3, in the microenvironment of the developing tumor vasculature, may affect, by means of TGFb release, the recruitment of mural cells and support the chronic immaturity of tumor vessels.
Encouraging results regarding the efficacy of a soluble TGFb receptor antagonists in reducing tumor spread have been documented (Muraoka et al., 2002; Yang et al., 2002) . The results of the present study address TGFb as a negative regulator of mural cell recruitment and identify a novel target for the TGFb receptor antagonist in tumor therapeutic strategy.
Materials and methods
Reagents
M199 medium (endotoxin-tested), minimum essential medium D-Val (MEM D-Val), bovine serum albumin (BSA), Sepharose-protein A, FITC-conjugated anti-rabbit IgG and antimouse IgG were all from Sigma (St Louis, MO, USA). Bovine calf serum BCS (endotoxin-tested) was obtained from HyClone (Logan, UT, USA). Trypsin and gelatin were purchased from Difco (Detroit, MI, USA). hIL-3 was a gift from Sandoz Pharma Ltd (Basel, Switzerland). Basic-fibroblast growth factor (bFGF) was from Euro Clone (Devon, UK). hVEGF IL-3 and vessel stabilization P Dentelli et al was from Chemicon International Inc. (Temecula, CA, USA). Nitrocellulose filters, HRP-conjugated anti-rabbit IgG and anti-mouse IgG, molecular weight markers and the chemiluminescence reagent (ECL) were from Amersham (Braunschweig, Germany). Matrigel basement membrane matrix was obtained from Becton Dickinson Labware (Bedford, MA, USA). Polycarbonate membrane 8 mm PVP free was from Corning Costar (Milan, Italy). Cycloheximide (CHX) was from Sigma. The presence of endotoxin contamination of hIL-3 preparation was tested by the Limulus amebocyte assay and the concentration was o0.1 ng/ml.
Antisera
Neutralizing rabbit polyclonal antiserum to hIL-3 and monoclonal anti-hVEGF antibody were from R&D Systems (Minneapolis, MN, USA). Polyclonal anti-hVEGF (for WB) antiserum, anti-VEGFR2/KDR antiserum, polyclonal and monoclonal anti-CD25 antibodies, and polyclonal anti-CD4 antiserum were obtained from Santa Cruz Biotechnology (Heidelberg, Germany). The monoclonal anti-hIL-3 antibody used for IF study was from BioSource International (Nivelles, Belgium). Anti-MMP-2, anti-CD105 and anti-TGFb 1 antibodies were purchased from Chemicon International Inc. (Temecula, CA, USA).
Cells
Human vascular SMC were isolated from the umbilical cord within 4 h of delivery. The vascular SMC layer was identified and characterized as described (Brizzi et al., 2001) . SMC from the II to IV passage were used for the experiments. Human ECs were isolated and characterized as described (Brizzi et al., 1993) . They were used for the experiments at early passage (II-III). Microvessel-derived CDC-HMEC-1 cell line (Brizzi et al., 1999a) was also used in some experiments. For the conditioned media (CM) transfer experiments, EC and SMC were grown until confluent in six-well culture plates in their respective medium. Then the cells were washed twice and incubated for 18 h in a serum-free medium with or without stimuli. After incubation the medium was recovered, spun at 2000 rpm and used throughout the experiments.
Immunoprecipitation and Western blot analysis
EC and SMC monolayers were incubated without or with hIL-3 (20 ng/ml) alone or in combination with the anti-IL-3 antiserum (40 mg/ml). After 18 h, supernatants were collected and divided into two aliquots: one was stored at À801C for the assessment of MMP-2 gelatinolytic activity and the other was used Â 40 concentrated for VEGF protein detection by Western blot analysis. After cell lysis, the protein content was determined by the Bradford technique and samples were normalized by appropriate dilution with medium and then processed as previously described (Brizzi et al., 1999b) . Unstimulated SMC or EC were lysed in DIM buffer for immunoprecipitation experiments and processed as described (Brizzi et al., 1999b) .
Immunofluorescence microscopy
Specimens from 20 in situ breast carcinomas were fixed, embedded in paraffin and processed for indirect immunofluorescence analysis as described (Brizzi et al., 2001) . Sections were double stained with monoclonal anti-hIL-3 (1 : 50) and polyclonal anti-CD25 (1 : 50) antibodies or with monoclonal anti-hIL-3 and polyclonal anti-CD4 (1 : 25) antibodies or with monoclonal anti-CD25 and polyclonal anti-CD4 antibodies.
Frozen or fixed and embedded in paraffin sections of Matrigel plugs from in vivo angiogenesis experiments were also subjected to indirect immunofluorescence using an anti-CD105 (1 : 100) antibody.
Migration assay
The migration of EC and SMC was performed in Boyden's chambers. The cells that passed across the filter (8-mm pore size) after addition in the lower compartment of the chamber of the vehicle alone (saline containing 0.25% BSA) or different stimuli were counted at Â 200 magnification. Chemotaxis of EC or SMC in Boyden's chambers was performed as previously described (Dentelli et al., 1999) .
Zymographic analysis of MMP activity
MMP-2 activity in the CM from cultured cells, collected as described above, were analysed by substrate gel electrophoresis. Briefly, zymography was performed by 10% PAGE copolymerized with 2 mg/ml of gelatin (Sigma). Equal amounts of samples were mixed with the sample buffer (5% SDS, 0.4 M Tris-HCl pH 6.8, 20% glycerol, 0.03% bromophenol blue) under nonreducing conditions and loaded into the gel. The gel was then washed in 2.5% (v/v) Triton X-100 for 2 h and then incubated in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.2% Brij-35 (Sigma), 10 mM CaCl 2 for 21 h at 371C. The gel was stained with 0.025% Coomassie blue and destained in 10% acetic acid and 30% methanol. Gelatinolytic activity appears as a clear band on a blue background. The amount of total proteins was used as the normalizing criterion.
Murine angiogenesis assay
Female SCID mice were used at 6-8 weeks of age. Angiogenesis was assayed as the growth of blood vessels from s.c. tissue into a solid gel of a basement membrane containing the test sample as previously described (Brizzi et al., 1999a; Dentelli et al., 1999) . The vessel area and the total Matrigel area were planimetrically assessed from stained sections, as described by Kibbey et al. (1992) . Considered vessels were only those structures possessing a patent lumen and containing RBC. Murine angiogenesis was expressed as the percentage7s.e.m. of the vessel area to the total Matrigel area. Animal procedures conformed to the Guide for Care and Use of Laboratory Resources (National Institutes of Health Publication No. 93-23, revised 1985) .
In vivo experimental protocol
The angiogenic effect of hIL-3 (20 ng/ml) in 0.5 ml of Matrigel was evaluated in the presence or in the absence of 64 U/ml heparin. In selected experiments, SMC were permanently labeled with a red fluorescent dye PKH26 (Sigma, St Louis, MO, USA) as described (Hirschi et al., 1998 (Hirschi et al., , 1999 . In all, 5 Â 10 5 red fluorescent-labeled SMC were included in the Matrigel plug with or without hIL-3 (20 ng/ml) or bFGF (10 ng/ml) and 64 U/ml heparin and injected s.c. into SCID mice for 6 or 10 days. Matrigel plugs were subsequently excised and divided into two parts: one was fixed in 10% buffered formalin and embedded in paraffin for HE staining, the other part was included in OCT and frozen at À801C for the immunofluorescence analysis. In some experiments, 5 Â 10 embedded in paraffin. SMC surrounding neovessels were analysed by immunofluorescence.
TGFb1 activity assay
CM from untreated and treated EC and SMC were collected and centrifuged to remove cell debris. Active and total TGFb1 (TGFb) levels were measured in full-strength CM using an enzyme-linked immunoassorbent assay (TGFb1 MTPL EIA; DRG GmbH, Marburg, Germany) as described by the manufacturer. Briefly, samples were acidified to separate the latency-associated peptide from the TGFb1 dimer, allowing the measurement of total TGFb1 (active plus latent components) and neutralized with NaOH. The results were compared with a standard curve. In all experiments reported, only the active form of TGFb1 has been considered.
Northern blot analysis
Cytoplasmic RNA was isolated from ECs by guanidinium thiocyanate/acid phenol-cloroform extraction (Chomczynski and Sacchi, 1987) . Northern blot analysis was performed according to the standard methods as previously described (Brizzi et al., 1993) . Filters were hybridized to 32 P randomlabeled DNA probes corresponding to TGFb and b-actin, washed to 30 min in 0.1 Â SSC and 1% SDS at 521C and exposed to an X-ray film for 2-4 days.
